Equivalence of MammaPrint array types in clinical trials and diagnostics

MammaPrint is an FDA-cleared microarray-based test that uses expression levels of the 70 MammaPrint genes to assess distant recurrence risk in early-stage breast cancer. The prospective RASTER study proved that MammaPrint Low Risk patients can safely forgo chemotherapy, which is further subject of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Beumer, Inès, Witteveen, Anke, Delahaye, Leonie, Wehkamp, Diederik, Snel, Mireille, Dreezen, Christa, Zheng, John, Floore, Arno, Brink, Guido, Chan, Bob, Linn, Sabine, Bernards, Rene, van ’t Veer, Laura, Glas, Annuska
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2016
Assuntos:
Preclinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4819553/
https://ncbi.nlm.nih.gov/pubmed/27002507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3764-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados